[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
May 8, 2013

Investments in Infrastructure for Diverse Research Resources and the Health of the Public

Author Affiliations

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine (Drs Psaty and Larson), Epidemiology (Dr Psaty), and Health Services (Dr Psaty), University of Washington, Seattle; and Group Health Research Institute, Group Health Cooperative, Seattle (Drs Psaty and Larson).

JAMA. 2013;309(18):1895-1896. doi:10.1001/jama.2013.3445

Active surveillance of drugs and devices in the postmarket setting is an essential component of the lifecycle approach to drug evaluation. The US Food and Drug Administration (FDA) Amendments Act of 2007 (PL 110-85) required the agency to develop “a postmarket risk identification and analysis system.” In response, scientists from the FDA and investigators from collaborating institutions have been actively and productively engaged in the creation of the Sentinel Initiative, including the Mini-Sentinel pilot program,1 which has become an exciting and powerful research resource.

First Page Preview View Large
First page PDF preview
First page PDF preview
×